April 8th, 2009 | 
Author: Ranbaxy Laboratories Limited, India’s largest pharmaceutical company announced that it has received an approval from the Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), to market and manufacture Topirimate tablets 25mg, 100mg & 200mg. This is Ranbaxy’s fourth ANDA approved in the last two months.
The application for the drug was submitted by Ranbaxy from the Ohm Laboratories manufacturing facility, located in North Brunswick, New Jersey, USA. The Office of Generic Drugs, USFDA, has determined the Ranbaxy formulation to be bioequivalent and as having the same therapeutic effect as that of the reference listed drug, Topamax by Ortho McNeil Janssen Pharmaceuticals, Inc.
Topirimate tablets are indicated as adjunctive therapy for adults and pediatric patients ages 2-16 years with partial onset seizures, or primary generalized tonic-clonic seizures, and in patients 2 years of age and older with seizures associated with Lennox-Gastaut syndrome.
“Ranbaxy is pleased to receive this final approval for Topirimate tablets. This is the fourth ANDA approval granted to Ranbaxy that has materialized in 2009 that is specific to Ohm Laboratories, “said Mr Jim Meehan, Vice President, Sales and Distribution, Ranbaxy Pharmaceuticals Inc, Jacksonville, Florida, USA.
BioSpectrum Asia is the most authoritative and influential source of information for life sciences industry. It is uniquely positioned as a specialized business-to-business information platform for life sciences industry in the Asia Pacific region.
Article Source: Ranbaxy receives approval from USFDA for Topirimate
